文献速递心境障碍

鲁拉西酮对比常规治疗改善双相I障碍心境平稳期患者认知损害的随机开放标签初步研究

Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study.
PubMed 文献 · Lancet Psychiatry · 2017-02-07

该随机开放标签初步研究纳入34例心境平稳期双相I障碍伴认知功能下降患者,比较鲁拉西酮辅助治疗与常规治疗6周对认知的影响。

要点

  • 鲁拉西酮辅助治疗6周可改善双相I障碍心境平稳期患者的总体认知评分。
  • 鲁拉西酮组不良事件报告率60%,常规治疗组13%,需关注耐受性。

核心结论

  • 鲁拉西酮辅助治疗对心境平稳期双相I障碍患者的认知改善提供初步证据,但需更大规模双盲试验进一步验证。

研究设计与样本

  • 随机、开放标签、初步研究,于加拿大温哥华UBC医院心境障碍中心招募19-65岁心境平稳期双相I障碍患者。
  • 采用区组大小为四的随机区组设计,将患者分配至常规治疗组或鲁拉西酮辅助治疗组(20-80 mg/日),疗程6周。
  • 由对分组设盲的研究协调员在基线和终点施测国际双相障碍学会神经认知评估成套测验(ISBD-BANC)。
  • 主要结局为总体认知评分变化,即ISBD-BANC多项测量的人口学校正t分数均值,在所有完成两次测试的患者中分析。

关键数值与推荐

  • 不良事件报告率:鲁拉西酮组60%(9例),常规治疗组13%(2例)。

临床怎么用

  • 对于心境平稳期双相I障碍伴认知功能下降的患者,鲁拉西酮辅助治疗可能作为改善认知的初步选择,但需权衡不良事件风险。
  • 鲁拉西酮辅助治疗平均剂量约48 mg/日、疗程6周的研究方案可供临床参考,但需在更大规模双盲试验证实前谨慎应用。

局限性

  • 样本量小(共34例),研究为开放标签设计,无法完全控制其他药物使用。
  • 研究为初步探索性试验,结果需更大规模双盲试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cognitive impairment is present in euthymic patients with bipolar disorder and correlates with impairments in everyday functioning. We aimed to examine the efficacy of lurasidone adjunctive therapy compared with treatment as usual (TAU) in improving cognition. METHODS: For this randomised, open-label, pilot study, we recruited patients aged 19-65 years with euthymic bipolar I disorder from the Mood Disorder Centre in UBC Hospital (Vancouver, Canada). We included patients who were taking lithium, or valproate, or an atypical antipsychotic, or a combination of these for mood stabilisation and who showed reduced cognitive functioning (SD≤ -0·25 relative to demographics-corrected norms) on either the Trail Making Test-B or the California Verbal Learning Test-II. Patients were randomly assigned using a randomised block design with a block size of four to TAU or lurasidone adjunctive therapy (20-80 mg/day) for 6 weeks. A research coordinator masked to group allocation administered the International Society for Bipolar Disorders Battery for Assessment of Neurocognition (ISBD-BANC) at baseline and at endpoint. The primary outcome was change in global cognition score, which consisted of the mean demographics-corrected t-score value of the several ISBD-BANC measures, analysed in all patients who completed both tests. This trial is registered on ClinicalTrials.gov, number NCT02147379. FINDINGS: Between July 2, 2014, and Oct 19, 2015, 34 patients were randomly allocated to lurasidone adjunctive therapy (17 patients) or TAU (17 patients). Two patients from each group did not complete the study. The mean lurasidone dose was 48·24 (SD 15·90) mg/day. Lurasidone adjunctive therapy was more effective than TAU in improving the primary efficacy measure of ISBD-BANC global cognition score (mean difference 2·92 [95% CI 0·27-5·57]; time × treatment interaction F=5·09; p=0·032). The between-group effect size (0·82) on baseline versus study-end difference scores in the ISBD global cognition score was of moderate to large magnitude. The magnitude of benefit with lurasidone adjunctive therapy in improving global cognition (effect size 0·46) was greater compared with the improvement observed in the TAU group (0·04). Adverse events were reported by nine (60%) patients in the luradisone group and two (13%) in the TAU group. INTERPRETATION: Our results provide some preliminary evidence for the efficacy of lurasidone in improving cognition in euthymic patients with bipolar I disorder. The strengths of this study were the characterisation of the sample and use of tests sensitive to cognitive impairment in bipolar disorder. Its limitations were the sample size and inability to completely control for other medication use. Larger double-blind trials are warranted to investigate this further. FUNDING: Sumitomo Dainippon Pharma.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Yatham LN, Mackala S, Basivireddy J, et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. Lancet Psychiatry. 2017. PMID: 28185899. doi:10.1016/S2215-0366(17)30046-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。